Worldwide Clinical Trials Acquires Catalyst Clinical Research to Strengthen Oncology Capabilities
Key Insights
Worldwide Clinical Trials (search) has entered a definitive agreement to acquire Catalyst Clinical Research (search), a specialized oncology (search) CRO known for early phase oncology trials and functional service provider capabilities.
The strategic combination will establish Worldwide as a leading oncology (search)-focused CRO while maintaining depth across multiple therapeutic areas and expanding global reach for clinical trials.
The integration will combine Catalyst's solutions with Worldwide's existing portfolio, offering customers expanded services for full-service, FSP resourcing, and hybrid models with enhanced technology platforms.
Worldwide Clinical Trials (search) has entered into a definitive agreement to acquire Catalyst Clinical Research (search), a specialized oncology (search) contract research organization (CRO) known for its expertise in early phase oncology trials and functional service provider (FSP) capabilities. The strategic acquisition aims to establish Worldwide as a leading oncology-focused CRO while maintaining depth across multiple therapeutic areas and expanding its global footprint for clinical trials.
Strategic Combination Creates Enhanced Oncology Platform
The transaction will see Catalyst Board chairman Nick Dyer join Worldwide's board of directors while Catalyst president and CEO Nik Morton will become part of Worldwide's executive leadership team. This integration combines Catalyst's two established solutions – Catalyst Oncology (search) and Catalyst Flex – with Worldwide's existing portfolio, offering customers expanded services for full-service, FSP resourcing, and hybrid models.
"Bringing Worldwide and Catalyst together elevates our capabilities in oncology (search) and provides a new solution for our collective customers," said Alistair Macdonald, Chief Executive Officer of Worldwide. "We are excited to add Catalyst's deep operational expertise and oncology credibility to our own well-known CNS specialist CRO capabilities to create a differentiated biotech-oriented oncology solution."
Technology Integration and Operational Excellence
The deal includes the adoption of complementary technology platforms and operational practices designed to enhance data efficiency and visibility across the development lifecycle. Customers will benefit from the addition of a scalable FSP model with integrated onshore/offshore service lines, while the combined organization leverages advanced business management tools and artificial intelligence to drive operational excellence.
Matt Jennings, Executive Chairman of Worldwide and Senior Operating Partner of Kohlberg (search), commented: "Integrating Catalyst will accelerate Worldwide's growth in oncology (search) and expand both its customer base and global reach simultaneously. Their specialized expertise, innovative platforms, and strong relationships with emerging biotech sponsors align perfectly with our vision for building a differentiated, technology-enabled CRO."
Expanded Global Footprint and Service Capabilities
Catalyst brings specialized early phase oncology (search) expertise that complements Worldwide's strength in late phase development, creating a comprehensive oncology platform with expanded global reach. The combination allows for delivery of FSP solutions to a broader customer base while maintaining both companies' commitment to scientific excellence and patient-centric solutions.
"By joining forces, Catalyst brings our specialized early phase oncology (search) expertise together with Worldwide's strength in late phase development, expanding our global footprint and delivering differentiated oncology solutions globally," said Nik Morton, President and Chief Executive Officer of Catalyst.
Transaction Details and Timeline
Worldwide will acquire Catalyst for an undisclosed amount, subject to customary closing conditions and regulatory approvals. The transaction is expected to close in Q1 2026. Both companies remain committed to ensuring a seamless transition for employees, customers, and partners.
Worldwide is a portfolio company of Kohlberg (search), based in Mount Kisco, N.Y., which invests in healthcare and services companies. Catalyst is a portfolio company of QHP Capital (search), based in Research Triangle Park, N.C., which focuses on life sciences and pharma services companies. BofA Securities (search) served as exclusive advisor and Smith Anderson (search) served as legal counsel to Catalyst, while Greenberg Traurig (search) served as legal counsel to Worldwide.
The combined organization will span over 60 countries with more than 4,500 team members, therapeutically focused on neuroscience (search), oncology (search), rare disease (search), and cardiometabolic and inflammatory disease (search).